Bio: Jane Larkindale serves as the Vice President of Clinical Science at PepGen. Jane has dedicated the past 15 years of her career to accelerating therapy development for rare diseases, with a focus on neuromuscular diseases. Prior to PepGen, Jane was Executive Director at Critical Path Institute where she conceived of and led the Rare Disease Cures Accelerator, Data and Analytics Platform and multiple disease specific consortia. Prior to the Critical Path Institute, Jane held the position of Vice President of Research Development at Friedreich’s Ataxia Research Alliance and the Muscular Dystrophy Association. Jane is a molecular biologist by training, having completed her D.Phil. (Ph.D.) in the Department of Plant Sciences at Oxford University, which she attended on a Rhodes Scholarship.